Total Funding
46
52
Total FundingPost-IPO Equity raised
Growth Score
-21 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
14217
Talphera focuses on the development and commercialization of therapies for the treatment of pain and other conditions.
Pamela Pierce Palmer: Founder & Chief Medical Officer
Vincent J. Angotti: Chief Executive OfficerPast Role: Xenoport, Chief Executive Officer & Director
About the Company
Talphera is a specialty pharmaceutical company developing and commercializing therapies in medically supervised settings. It offers NanoTab, a tablet for oral transmucosal administration. The company also provides Sufentanil NanoTab PCA system, a sublingual patient-controlled analgesia system with a drug/device combination product candidate
for the management of acute postoperative pain in hospital settings; Sufentanil NanoTab BTP management systems for the treatment option for patients with cancer pain; and Sufentanil/Triazolam NanoTab, which provides analgesia and sedation for minor outpatient procedures.
Women Founded
